- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT06447480
Randomisert klinisk studie for å sammenligne oralt isotretinoin med standardbehandling hos pasienter med moderat akne. (ETHNIC)
Randomisert klinisk studie for å sammenligne oral isotretinoin med standardbehandling hos pasienter med moderat akne hudfarge: ETNISK studie
In Dermatology, assessment of people of color remains underrepresented in RCTs (<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 3
Kontakter og plasseringer
Studiekontakt
- Navn: Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-post: passeron.t@chu-nice.fr
Studer Kontakt Backup
- Navn: Emmanuelle Pradelli
- Telefonnummer: +33492036488
- E-post: pradelli.e@chu-nice.fr
Studiesteder
-
-
-
Argenteuil, Frankrike
- Rekruttering
- CH D'argenteuil
-
Ta kontakt med:
- Emmanuel MAHE, Ph
- E-post: emmanuel.mahe@ch-argenteuil.fr
-
Underetterforsker:
- emmanuel Mahé, Ph
-
Brest, Frankrike
- Rekruttering
- Cabinet Dermatologique Brest 1
-
Ta kontakt med:
- Nicolas Jouan, Ph
- E-post: nicole.jouan@wanadoo.fr
-
Underetterforsker:
- Nicole Jouan, Ph
-
Brest, Frankrike
- Rekruttering
- Cabinet Dermatologique Brest 2
-
Ta kontakt med:
- Martine Schollhammer, Ph
- E-post: Martine.schollhammer@wanadoo.fr
-
Underetterforsker:
- Martine Schollhammer, Ph
-
Cenon, Frankrike
- Har ikke rekruttert ennå
- Cabinet dermatologique Cenon
-
Ta kontakt med:
- Jean-Michel Amici, Ph
- E-post: jmamici@gmail.com
-
Underetterforsker:
- Jean-Michel Amici, Ph
-
Gradignan, Frankrike
- Rekruttering
- Cabinet dermatologique gradignan
-
Ta kontakt med:
- Sandra Ly, Ph
- E-post: dr.sandra.ly67@gmail.com
-
Underetterforsker:
- Sandra Ly, Ph
-
La Réunion, Frankrike
- Rekruttering
- CHU de la réunion
-
Ta kontakt med:
- Antoine Bertolotti, PhD
- E-post: antoine_bertolotti@yahoo.fr
-
Underetterforsker:
- antoine bertolotti, PhD
-
Paris, Frankrike
- Har ikke rekruttert ennå
- Cabinet dermatologique privé
-
Ta kontakt med:
- Pierre Schneider, Ph
- E-post: drpierreschneider@gmail.com
-
Underetterforsker:
- Pierre Schneider, Ph
-
Paris, Frankrike
- Rekruttering
- Ambroise paré
-
Ta kontakt med:
- Tu-Anh Duong, Ph
- E-post: tu-anh.duong@aphp.fr
-
Underetterforsker:
- Tu-Anh Duong, Ph
-
Paris, Frankrike
- Rekruttering
- Cabinet dermatologique
-
Hovedetterforsker:
- Christelle Comte
-
Ta kontakt med:
- Christelle Comte
- Telefonnummer: 06.50.72.89.09
- E-post: Dr.ch.comte@gmail.com
-
Paris, Frankrike
- Rekruttering
- CH Avicenne - APHP
-
Ta kontakt med:
- Gérome Bohelay, Ph
- E-post: gerome.bohelay@gmail.com
-
Underetterforsker:
- Gérôme Bohelay, Ph
-
Poitiers, Frankrike
- Rekruttering
- CHU de Poitiers
-
Ta kontakt med:
- Da Hee Pitaud, Ph
- Telefonnummer: 0549444459
- E-post: Da-hee.pitaud@chu-poitiers.fr
-
Hovedetterforsker:
- Da Hee Pitaud
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrike, 06200
- Rekruttering
- CHU de Nice - Hôpital de l'Archet
-
Ta kontakt med:
- Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-post: passeron.t@chu-nice.fr
-
Hovedetterforsker:
- Thierry Passeron, PhD
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrike, 33000
- Rekruttering
- CHU de Bordeaux
-
Ta kontakt med:
- Marie Beylot-Barry, PhD
- E-post: marie.beylot-barry@chu-bordeaux.fr
-
Underetterforsker:
- Marie Beylot-Barry, PhD
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrike, 44 000
- Rekruttering
- CHU de Nantes
-
Ta kontakt med:
- Marie Lemoigne, Ph
- E-post: marie.lemoigne@chu-nantes.fr
-
Underetterforsker:
- Marie Lemoigne, Ph
-
-
Seine-maritime
-
Rouen, Seine-maritime, Frankrike, 76000
- Rekruttering
- chu de Rouen
-
Ta kontakt med:
- Pascal Joly, PhD
- E-post: pascal.joly@chu-rouen.fr
-
Underetterforsker:
- pascal joly, PhD
-
-
Var
-
Sainte-Maxime, Var, Frankrike, 83000
- Rekruttering
- Cabinet de dermatologie St Maxime
-
Ta kontakt med:
- Marc Reverte, Ph
- E-post: dr.reverte@orange.fr
-
Underetterforsker:
- Marc Reverte, Ph
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrike, 75000
- Rekruttering
- APHP
-
Ta kontakt med:
- Coralie Lheure, PhD
- E-post: coralie.lheure@aphp.fr
-
Underetterforsker:
- Coralie LHEURE, PhD
-
-
-
-
-
Cayenne, Fransk Guyana, 97306
- Rekruttering
- CH de Cayenne 3 Avenue Alexis Blaise, BP6006
-
Ta kontakt med:
- Romain BLAIZOT
- Telefonnummer: 0594397799
- E-post: romain.blaizot@ch-cayenne.fr
-
Ta kontakt med:
- william faurous
- Telefonnummer: 0594397799
- E-post: william.faurous <william.faurous@ch-cayenne.fr>
-
Hovedetterforsker:
- Romain Blaizot
-
Fort-de France, Fransk Guyana
- Rekruttering
- Cabinet de dermatologie DERMACLINIC 972
-
Ta kontakt med:
- emilie baubion, Ph
- Telefonnummer: 0767292250
- E-post: dr.emilie.baubion@gmail.com
-
Hovedetterforsker:
- Emilie Baubion
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Women and men between 13 and 30-year-old
- Skin type IV, V and VI according to Fitzpatrick skin types
- Moderate acne as defined by the French Society of Dermatology recommendations based on ECLA grading https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Patients must have a cell phone able to take selfies pictures with a minimum definition of 5Mb.
- Signed informed consent
- Affiliation to French social coverage.
Exclusion Criteria:
- Mild and severe acne (ECLA grading : French recommendations) (https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Past cure of oral isotretinoin
- Past cure of systemic antibiotics for acne in the last 6 months
- Phototype I-III patients
- Abnormal hemogram, liver enzyme, cholesterol, triglycerides at baseline
- Pregnancy: female patient of childbearing potential will undergo a pregnancy test (plasmatic β-hCG)
- Breast-feeding patients
- Refusal of effective contraception for women
- Contra-indications to oral isotretinoin, doxycycline, lymecycline, topical adapalene/tretinoin
- Vulnerable people: adult under guardianship or deprived of freedom
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Drug group
Patients will be followed every month for 6 months in the group isotretinoin. Patients will start at the dose of 0.5 mg/kg/d. If tolerance is poor, the dose could be decrease to 0.25mg/d. After 3 months, following the recommendations the dose could be increase up to 1mg/kg/d depending on the efficacy. |
The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d. After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended. |
|
Aktiv komparator: Doxycycline
Patients will be followed at 3 and 6 months in the group "standard of care". They will be prescribed topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d. |
Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of score acne-related pigmentation
Tidsramme: at 6 months
|
To assess the superiority after 6 months of a first line oral isotretinoin treatment of moderate facial acne in skin of color patients compared to the current standard of care on the severity of ARP. |
at 6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life of patient
Tidsramme: at 6 months
|
Quality of life will be evaluated with the Acne-specific Quality of Life questionnaire (Acne-QoL) |
at 6 months
|
|
Number of adverse events
Tidsramme: during 6 months
|
A special focus on scars will be performed using an Investigator Global Assessment score (0 no scar, 1 mild scarring, 2 moderate, 3 severe) over the study period. |
during 6 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Hovedetterforsker: Thierry Passeron, PhD, CHU de Nice, Service de Dermatologie
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Hudsykdommer
- Akneiforme utbrudd
- Talgkjertelsykdommer
- Hud- og bindevevssykdommer
- Acne vulgaris
- Organiske kjemikalier
- Retinoider
- Karotenoider
- Polyener
- Alkenes
- Hydrokarboner, acyklisk
- Hydrokarboner
- Cyclohexenes
- Cyclohexanes
- Cycloparaffins
- Hydrokarboner, alicyklisk
- Hydrokarboner, syklisk
- Terpener
- Pigmenter, biologisk
- Biologiske faktorer
- Isotretinoin
- Floderm topical cream
Andre studie-ID-numre
- 22-APN-02
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .